Previous 10 |
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Freightcar America, Inc. (NASDAQ:RAIL), Star Bulk Carriers Corp. (NASD...
Adamas Pharma's GOCOVRI shows long-term treatment effect in late-stage Parkinson's study Adamas Pharma ( ADMS ) has had a bad few months lately, with 3 reported deaths in GOCOVRI patients, looming competition from a similar drug, payer issues and problem with pricing. While the 3 deaths ...
After the product candidate of VistaGen (VTGN), AV-101, received Fast Track designation, the shares went to 12x its book value per share, which seems overvalued as compared to peers. It does not seem the right time to acquire shares. With that, investors should recognize the revenue pote...
Final results from a two-year open-label Phase 3 clinical trial, EASE LID 2 , evaluating Adamas Pharmaceuticals' ( ADMS -3.1% ) GOCOVRI (amantadine) in patients with Parkinson's disease (PD) showed a sustained treatment effect. The data were presented at the International Congress of P...
GOCOVRI was generally well tolerated and the safety profile was consistent with previously reported data for up to two years Results show a comparable 35% reduction from baseline in dyskinesia and OFF was achieved across all subgroups naïve to GOCOVRI as measured by MDS-UPDRS, Pa...
EMERYVILLE, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted nine new employees the option to purchase an aggregate of 49,210 shares of the company’...
Natera (NASDAQ: NTRA ) initiated with Neutral rating and $26 (11% upside) price target at JPMorgan. More news on: Natera, Evolent Health, Eli Lilly and Company, Healthcare stocks news, Stocks on the move, , Read more ...
EMERYVILLE, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today announced that pooled Phase 3 data of GOCOVRI™ (amantadine) ...
News, Short Squeeze, Breakout and More Instantly...
Adamas Pharmaceuticals Inc. Company Name:
ADMS Stock Symbol:
NASDAQ Market:
Adamas Pharmaceuticals Inc. Website:
Supernus Pharmaceuticals (NASDAQ: SUPN) recently announced that it's acquiring Adamas Pharmaceuticals (NASDAQ: ADMS) . In this Motley Fool Live video recorded on Oct. 13 , Motley Fool contributors Keith Speights and Brian Orelli discuss why Supernus' planned acq...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Adamas Pharmaceuticals, Inc. Announces Definitive Agreement to be Acquired by Supernus Pharmaceuticals, Inc” Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) surged ove...
Supernus Pharmaceuticals Inc ( NASDAQ: SUPN ) recently announced that it had entered a definitive contract to acquire Adamas Pharmaceuticals ( NASDAQ: ADMS ). Supernus is to purchase this company a tender offer that was worth about $8.10 per share. The aggregate was roug...